GlassScriptPhysician profile
Federico Albrecht
NPI 1366439689
$109,595.00
in general payments reported to CMS, 2019-2025
26 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $14K · 2021: $27K · 2022: $6,295 · 2023: $2,522 · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $10K · Food and Beverage: $4,455 · Travel and Lodging: $4,198 · Education: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,218.00 |
| Consulting Fee | $10,254.00 |
| Food and Beverage | $4,455.39 |
| Travel and Lodging | $4,197.60 |
| Education | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34,018.33 | 2019-2025 | Gilotrif |
| Lilly USA, LLC | $22,671.80 | 2019-2024 | Cyramza, Retevmo |
| Jazz Pharmaceuticals INC. | $15,328.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $9,430.27 | 2019-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $9,081.02 | 2019-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $8,168.92 | 2021-2024 | Libtayo |
| Partner Therapeutics, INC. | $3,319.79 | 2025 | Bizengri |
| Genzyme Corporation | $1,824.00 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,214.42 | 2021-2024 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $744.50 | 2021-2025 | Tagrisso, Imfinzi, Datroway |
| Emd Serono, INC. | $623.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $260.74 | 2023-2025 | Enhertu, Datroway |
| Novocure INC. | $245.89 | 2023-2025 | Optune Lua (Novottf-200t) |
| Array Biopharma INC | $208.30 | 2023-2025 | Lorbrena, Xalkori, Mektovi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $167.95 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Eagle Pharmaceuticals, INC. | $148.80 | 2022 | |
| Coherus Oncology, INC. | $129.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2020 | |
| Mirati Therapeutics, INC. | $122.99 | 2023 | Krazati |
| Amgen INC. | $121.87 | 2022 | |
| Nuvation Bio INC. | $75.57 | 2025 | Ibtrozi |
| Rigel Pharmaceuticals, INC. | $33.01 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $29.70 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.